by Richard Daverman, PhD, and Henry Ye
January 25, 2013 -- Huapont Pharma said its wholly-owned subsidiary Chongqing Huapont Pharm Co., has signed a letter of intent to partner with Yes Biotech, a Canadian company, to develop the latter company’s innovative psoriasis/eczema treatment. Both companies have an interest in dermatology products, and Yes Biotech already markets a psoriasis salve. Terms of the agreement were not disclosed, but it seems Huapont will make an investment in Yes Biotech. More details....
Stock Symbol: (SHE: 002004)
